Pure Global AI
NCT06235905Recruiting

Open-Label of SPN-820 in Adults With Major Depressive Disorder

An Open-Label, Single-Group Study to Evaluate the Efficacy and Safety of SPN-820 in Adults With Major Depressive Disorder
Navitor Pharmaceuticals, Inc.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
NV-5138
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Navitor Pharmaceuticals, Inc.
Location
Rochester, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Feb 15, 2024
End date
Oct 15, 2024
Enrollment
50 participants
Primary outcome

Evaluation of the efficacy of SPN-820 administered once every 3 days as measured by the Hamilton Depression Rating Scale-6 Items

Summary

This study will evaluate the efficacy and safety of SPN-820 in Adults With Major Depressive
 Disorder (MDD)

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06235905
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06235905 through Pure Global AI's free database. This Phase 2 trial is sponsored by Navitor Pharmaceuticals, Inc. and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.